Scott Myers

Title: Scott Myers: Innovator in Neuropharmacology

Introduction

Scott Myers is a prominent inventor based in Atlanta, GA (US). He has made significant contributions to the field of neuropharmacology, particularly through his innovative research and development of compounds that target specific receptors in the brain. His work has the potential to impact various neurological conditions and disorders.

Latest Patents

Scott Myers holds a patent for "GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH." This patent discloses compounds that selectively inhibit GluN2B-containing N-methyl-D-aspartic acid receptors (NM/DARs). The compounds are designed to target GluN2B over other subunits such as GluN2A, GluN2C, and GluN2D. Notably, these compounds exhibit enhanced potency at a more acidic pH compared to physiological pH. The patent also includes pharmaceutical formulations containing these compounds and methods for treating various conditions, disorders, and diseases, including stroke, cerebral ischemia, and neurodegenerative diseases.

Career Highlights

Throughout his career, Scott Myers has worked with esteemed institutions such as Emory University and Neurop, Inc. His research has focused on developing innovative solutions for complex neurological issues, showcasing his dedication to advancing medical science.

Collaborations

Scott has collaborated with notable professionals in his field, including Dennis C. Liotta and Stephen F. Traynelis. These collaborations have further enriched his research and contributed to the development of effective therapeutic strategies.

Conclusion

Scott Myers is a distinguished inventor whose work in neuropharmacology has the potential to transform the treatment of various neurological conditions. His innovative compounds and dedication to research exemplify the impact of inventors in advancing medical science.